The American Urological Association (AUA)’s updated Prostate-Specific Antigen Best Practice Statement first at the annual meeting of the AUA in April, has been published in the November issue of the Journal of Urology.

The statement includes the controversial guidance that the prostate-specific antigen (PSA) test should be offered to men starting at the age of 40 years — which one critic has said is not supported by “any convincing evidence.”

The update also reiterates the AUA’s position that prostate cancer screening with PSA is a matter of individual choice.

There is no single standard that applies to all men.